nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND.sqm

被引：0
|
作者：
Gridelli, C. [1 ]
McCleod, M. [2 ]
Morgensztern, D. [3 ]
Daniel, D. B. [4 ]
Page, R. [5 ]
Wehler, T. [6 ]
Juan, O. [7 ]
Levy, B. [8 ]
Ardizzoni, A. [9 ]
Berry, T. [10 ]
Chen, T. [10 ]
Trunova, N. [10 ]
Jotte, R. [11 ]
机构：
[1] SG Moscati Hosp, Oncol, Avellino, Italy
[2] Florida Canc Specialists, Oncol, Cape Coral, FL USA
[3] Washington Univ, Schoo Med, Oncol, St Louis, MO USA
[4] Tennessee Oncol, Oncol, Chattanooga, TN USA
[5] Ctr Canc & Blood Disorders, Oncol, Ft Worth, TX USA
[6] Univ Hosp Mainz, Oncol, Mainz, Germany
[7] Hosp Univ & Politecn La Fe, Med Oncol, Valencia, Spain
[8] Beth Israel Deaconess Med Ctr, Oncol, New York, NY 10003 USA
[9] Univ iPolitecn La Fe, Oncol, Valencia, Italy
[10] Celgene Corp, Oncol, Summit, NJ USA
[11] Rocky Mt Canc Ctr, Oncol Hematol, Denver, CO USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1369P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] nab-Paclitaxel (nab-P) plus carboplatin (C) as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC): Clinical outcomes by treatment cycle
    Gridelli, C.
    Li, L.
    O'Brien, M.
    Ong, T. J.
    Pirker, R.
    Socinski, M. A.
    Thomas, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S638 - S639
  • [22] Interim results from the phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) in pancreatic cancer (PC), non-small cell lung cancer (NSCLC), and metastatic breast cancer (mBC)
    Wainberg, Z. A.
    George, B.
    Goldman, J. W.
    Hochster, H. S.
    Kelly, K.
    Ko, A.
    O'Dwyer, P. J.
    Trunova, N.
    Waterhouse, D.
    Soliman, H. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S103 - S103
  • [23] Quality of life (QoL) in elderly patients (pts) with advanced NSCLC treated with nab-paclitaxel (nab-P) plus carboplatin (C): Interim results from the ABOUND. 70+study
    Weiss, J.
    Kim, E.
    Amiri, K. I.
    Anderson, E.
    Dakhil, S.
    Haggstrom, D.
    Jotte, R.
    Konduri, K.
    Modiano, M.
    Ong, T. J.
    Sanford, A.
    Smith, D.
    Socoteanu, M.
    Goldman, J.
    Langer, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results
    Gentzler, R. D.
    Mohindra, N. A.
    Hanna, N.
    Chae, Y. K.
    Jalal, S. I.
    Hall, R.
    Villaflor, V. M.
    Reckamp, K. L.
    Koczywas, M.
    Sullivan, D.
    Wood, L.
    Patel, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 236 - 236
  • [25] Analysis of Predictive Factors in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) as First-Line Therapy for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hirsh, V.
    Page, R. D.
    Ko, A.
    Renshler, M.
    Socinski, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S43 - S43
  • [26] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) plus carboplatin (C) in advanced NSCLC: safety and efficacy results
    Waterhouse, David M.
    George, Ben
    Gutierrez, Martin
    Otterson, Greg A.
    Ko, Amy
    Ong, Teng Jin
    Stergiopoulos, Sotirios
    Trunova, Nataliya
    Kelly, Karen
    CANCER RESEARCH, 2016, 76
  • [27] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts
    George, B.
    Kelly, K.
    Ko, A.
    Soliman, H.
    Trunova, N.
    Wainberg, Z.
    Waterhouse, D.
    O'Dwyer, P.
    Hochster, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hirsh, V.
    Owen, S. P.
    Ko, A.
    Renschler, M.
    Socinski, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S21 - S21
  • [29] Efficacy and safety of weekly nab-paclitaxel plus carboplatin advanced non-small cell lung cancer
    Satouchi, Miyako
    Okamoto, Isamu
    Sakai, Hiroshi
    Yamamoto, Nobuyuki
    Ichinose, Yukito
    Ohmatsu, Hironobu
    Nogami, Naoyuki
    Takeda, Koji
    Mitsudomi, Tetsuya
    Kasahara, Kazuo
    Negoro, Shunichi
    LUNG CANCER, 2013, 81 (01) : 97 - 101
  • [30] nab-Paclitaxel plus Carboplatin in Advanced Non-Small Cell Lung Cancer NSCLC: Dose Modification Analysis
    Postmus, Pieter E.
    O'Brien, Mary E. R.
    Socinski, Mark A.
    Li, Li
    Ong, Teng Jin
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S658 - S658
12345